DK1259513T3 - Ny krystallinsk form af N-[4-[2-(2-amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutaminsyre og fremgangsmåder til dets fremstilling - Google Patents

Ny krystallinsk form af N-[4-[2-(2-amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutaminsyre og fremgangsmåder til dets fremstilling

Info

Publication number
DK1259513T3
DK1259513T3 DK01906554T DK01906554T DK1259513T3 DK 1259513 T3 DK1259513 T3 DK 1259513T3 DK 01906554 T DK01906554 T DK 01906554T DK 01906554 T DK01906554 T DK 01906554T DK 1259513 T3 DK1259513 T3 DK 1259513T3
Authority
DK
Denmark
Prior art keywords
pyrrolo
pyrimidin
dihydro
benzoyl
oxo
Prior art date
Application number
DK01906554T
Other languages
Danish (da)
English (en)
Inventor
Susan Marie Reutzel-Edens
Erik Christopher Chelius
Sharon Van Den Berghe Snorek
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22679017&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1259513(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK1259513T3 publication Critical patent/DK1259513T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
DK01906554T 2000-02-25 2001-02-12 Ny krystallinsk form af N-[4-[2-(2-amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutaminsyre og fremgangsmåder til dets fremstilling DK1259513T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18496400P 2000-02-25 2000-02-25
PCT/US2001/001229 WO2001062760A2 (en) 2000-02-25 2001-02-12 A NOVEL CRYSTALLINE FORM OF N-[4-[2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO[2,3-d]PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMIC ACID AND PROCESS THEREFOR

Publications (1)

Publication Number Publication Date
DK1259513T3 true DK1259513T3 (da) 2004-01-12

Family

ID=22679017

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01906554T DK1259513T3 (da) 2000-02-25 2001-02-12 Ny krystallinsk form af N-[4-[2-(2-amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutaminsyre og fremgangsmåder til dets fremstilling

Country Status (36)

Country Link
US (1) US7138521B2 (zh)
EP (1) EP1259513B1 (zh)
JP (1) JP4846158B2 (zh)
KR (1) KR100744917B1 (zh)
CN (1) CN1183135C (zh)
AR (1) AR029471A1 (zh)
AT (1) ATE249462T1 (zh)
AU (1) AU777047B2 (zh)
BR (1) BR0108604A (zh)
CA (1) CA2400155C (zh)
CO (1) CO5261585A1 (zh)
CZ (1) CZ303772B6 (zh)
DE (1) DE60100750T2 (zh)
DK (1) DK1259513T3 (zh)
DZ (1) DZ3283A1 (zh)
EA (1) EA004684B1 (zh)
EG (1) EG24073A (zh)
ES (1) ES2206403T3 (zh)
HK (1) HK1051856A1 (zh)
HR (1) HRP20020701B1 (zh)
HU (1) HU229704B1 (zh)
IL (2) IL150480A0 (zh)
MX (1) MXPA02008242A (zh)
MY (1) MY124784A (zh)
NO (1) NO323422B1 (zh)
NZ (1) NZ519796A (zh)
PE (1) PE20011082A1 (zh)
PL (1) PL208061B1 (zh)
PT (1) PT1259513E (zh)
SI (1) SI1259513T1 (zh)
SK (1) SK287375B6 (zh)
SV (1) SV2002000321A (zh)
TW (1) TWI237024B (zh)
UA (1) UA72791C2 (zh)
WO (1) WO2001062760A2 (zh)
ZA (1) ZA200205265B (zh)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100364993C (zh) * 2003-05-30 2008-01-30 江苏恒瑞医药股份有限公司 培美曲噻盐及其制备方法
CN100364994C (zh) * 2004-11-25 2008-01-30 重庆医药工业研究院有限责任公司 培美曲塞二钠的一种新晶型及其制备方法
CN101299921A (zh) * 2005-11-04 2008-11-05 默克公司 用saha和硼替佐米治疗癌症的方法
AU2006311820A1 (en) * 2005-11-04 2007-05-18 Merck Sharp & Dohme Corp. Methods of using SAHA and erlotinib for treating cancer
ATE492547T1 (de) 2006-08-14 2011-01-15 Sicor Inc Verfahren zur herstellung lipophiler pharmazeutisch akzeptabler salze aus pemetrexed- disäure
JP2008543974A (ja) * 2006-08-14 2008-12-04 シコール インコーポレイティド ペメトレキセド二酸の結晶形およびその調製方法
JP2008543975A (ja) 2006-08-14 2008-12-04 シコール インコーポレイティド 高度に純粋なペメトレキセド二酸およびその調製方法
US7994180B2 (en) * 2006-08-14 2011-08-09 Sicor Inc. Processes for preparing intermediates of pemetrexed
CN101528037A (zh) * 2006-11-03 2009-09-09 默克公司 使用saha和硼替佐米治疗多发性骨髓瘤的方法
MX2009010568A (es) * 2007-04-03 2009-10-22 Reddys Lab Ltd Dr Formas solidas de pemetrexed.
CN101417998B (zh) 2007-10-24 2012-10-24 重庆医药工业研究院有限责任公司 一种培美曲塞盐的纯化方法
EP2072518A1 (en) * 2007-12-23 2009-06-24 Sun Pharma Advanced Research Company Limited Stable Amorphous Form of Pemextred Disodium
WO2010028105A2 (en) * 2008-09-08 2010-03-11 Dr. Reddy's Laboratories Ltd. Amorphous pemetrexed disodium
WO2010030598A2 (en) * 2008-09-11 2010-03-18 Dr. Reddy's Laboratories Limited Pharmaceutical formulations comprising pemetrexed
CN101684121B (zh) * 2008-09-22 2013-04-03 重庆医药工业研究院有限责任公司 培美曲塞二酸的新晶型及其制备方法
CN102050825B (zh) * 2009-11-05 2014-12-17 上海创诺制药有限公司 制备培美曲塞二钠2.5水结晶的方法
WO2011064256A1 (en) 2009-11-24 2011-06-03 Azad Pharmaceutical Ingredients Ag A new crystalline form of pemetrexed disodium
CN102372719B (zh) * 2010-08-26 2013-10-30 齐鲁制药有限公司 培美曲塞二甲酯对甲苯磺酸盐晶型及其制备方法
KR101069128B1 (ko) * 2011-03-10 2011-09-30 건일제약 주식회사 페메트렉시드 또는 그의 염을 포함하는 항산화제-비함유 주사용 용액 형태의 약학적 제제의 제조방법
US9051322B2 (en) 2011-03-23 2015-06-09 Scinopharm Taiwan, Ltd. Process for the production of a pemetrexed salt
ES2639639T3 (es) * 2011-03-25 2017-10-27 Scinopharm Taiwan, Ltd. Proceso para la producción de pemetrexed disódico
ITRM20120398A1 (it) 2012-08-08 2014-02-09 Berlin Chemie Ag Procedimento di sintesi pemetrexed e suo sale di lisina.
CN102911176B (zh) * 2012-10-10 2015-07-22 德州德药制药有限公司 一种培美曲塞二钠的制备方法
WO2014060959A1 (en) * 2012-10-17 2014-04-24 Shilpa Medicare Limited Crystalline pemetrexed dipotassium process
US20150359898A1 (en) 2013-02-06 2015-12-17 Cipla Limited Pemetrexed Complexes and Pharmaceutical Compositions Containing Pemetrexed Complexes
WO2014167585A1 (en) 2013-04-12 2014-10-16 Actavis Group Ptc Ehf. Pemetrexed formulation
KR101485243B1 (ko) * 2013-05-08 2015-01-21 씨제이헬스케어 주식회사 안정화된 페메트렉시드 제제
JP6094388B2 (ja) * 2013-06-07 2017-03-15 ニプロ株式会社 ペメトレキセドを含む注射用組成物
ES2657944T3 (es) 2013-06-14 2018-03-07 Synthon B.V. Sal estable de arginina de pemetrexed y composiciones que la comprenden
JP2016527227A (ja) 2013-07-16 2016-09-08 ドクター レディズ ラボラトリーズ リミテッド ペメトレキセドトロメタミン塩の新規な結晶形
JP6313317B2 (ja) 2013-10-03 2018-04-18 富士フイルム株式会社 注射液製剤及びその製造方法
NZ630292A (en) * 2013-11-25 2015-02-27 Shilpa Medicare Ltd Process for crystalline pemetrexed dipotassium salt
NZ630299A (en) 2014-06-30 2014-11-28 Shilpa Medicare Ltd Pemetrexed dipotassium formulations
CA2962383C (en) 2014-10-30 2019-10-08 Scinopharm Taiwan, Ltd. Crystalline forms of pemetrexed diacid and manufacturing processes therefor
CN105566328B (zh) * 2014-11-06 2018-04-24 博瑞生物医药（苏州）股份有限公司 培美曲塞二酸多晶型的制备方法
EP3804686B1 (en) * 2017-10-10 2023-08-30 Sun Pharmaceutical Industries Ltd Intravenous infusion dosage form for pemetrexed

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO169490C (no) * 1988-03-24 1992-07-01 Takeda Chemical Industries Ltd Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrrolopyrimidinderivater
KR0162654B1 (ko) * 1989-12-11 1998-11-16 알렌 제이. 시니스갤리 N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체
US5416211A (en) * 1992-09-25 1995-05-16 Eli Lilly And Company Process for preparing 5-substituted pyrrolo-[2,3-d]pyrimidines
CA2263907A1 (en) * 1996-08-30 1998-03-05 Christopher Leighon Jordan Nonclassical pyrrolo[2,3-d]pyrimidine antifolates
BR9812524A (pt) * 1997-09-26 2000-07-25 Lilly Co Eli Processos e intermediários utilizáveis para produzir antifolatos
ZA987550B (en) * 1997-09-26 2000-02-21 Lilly Co Eli Processes and intermediates useful to make antifolates.
AU6890800A (en) * 1999-08-23 2001-03-19 Eli Lilly And Company A novel crystalline form of disodium n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-D]- pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid salt and processes therefor

Also Published As

Publication number Publication date
MXPA02008242A (es) 2002-11-29
IL150480A (en) 2007-12-03
CA2400155C (en) 2009-09-15
ES2206403T3 (es) 2004-05-16
IL150480A0 (en) 2002-12-01
CN1406238A (zh) 2003-03-26
SI1259513T1 (en) 2003-12-31
SK287375B6 (sk) 2010-08-09
ATE249462T1 (de) 2003-09-15
EP1259513B1 (en) 2003-09-10
NZ519796A (en) 2003-01-31
SV2002000321A (es) 2002-07-16
DE60100750D1 (de) 2003-10-16
EA004684B1 (ru) 2004-06-24
BR0108604A (pt) 2002-11-19
US20030216416A1 (en) 2003-11-20
PL208061B1 (pl) 2011-03-31
KR100744917B1 (ko) 2007-08-01
EP1259513A2 (en) 2002-11-27
NO20023974L (no) 2002-08-21
MY124784A (en) 2006-07-31
AU777047B2 (en) 2004-09-30
EG24073A (en) 2008-05-11
NO323422B1 (no) 2007-04-30
AR029471A1 (es) 2003-07-02
PE20011082A1 (es) 2001-10-22
WO2001062760A2 (en) 2001-08-30
JP2003530321A (ja) 2003-10-14
US7138521B2 (en) 2006-11-21
JP4846158B2 (ja) 2011-12-28
WO2001062760A3 (en) 2001-12-06
UA72791C2 (uk) 2005-04-15
CZ20022875A3 (cs) 2003-02-12
CN1183135C (zh) 2005-01-05
CA2400155A1 (en) 2001-08-30
HU229704B1 (en) 2014-05-28
AU3445101A (en) 2001-09-03
SK11862002A3 (sk) 2003-01-09
HRP20020701B1 (en) 2011-02-28
DE60100750T2 (de) 2004-07-29
HUP0204232A3 (en) 2006-01-30
HK1051856A1 (en) 2003-08-22
DZ3283A1 (fr) 2001-08-30
KR20020075449A (ko) 2002-10-04
PL356423A1 (en) 2004-06-28
CO5261585A1 (es) 2003-03-31
HRP20020701A2 (en) 2003-12-31
TWI237024B (en) 2005-08-01
NO20023974D0 (no) 2002-08-21
HUP0204232A2 (hu) 2003-04-28
EA200200905A1 (ru) 2003-02-27
ZA200205265B (en) 2003-11-11
PT1259513E (pt) 2004-02-27
CZ303772B6 (cs) 2013-05-02

Similar Documents

Publication Publication Date Title
DK1259513T3 (da) Ny krystallinsk form af N-[4-[2-(2-amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutaminsyre og fremgangsmåder til dets fremstilling
NO20050524L (no) Fremgangsmater for fremstillingen av 4-[[4-[[4-(2-cyanoetenyl)-2,6-dimetylfenyl]amino]-2-pyrimidinyl]amino]benzonitril
DK1443925T3 (da) Naphthyridinderivater, deres fremstilling og deres anvendelse som inhibitorer af phosphodiesteraseisoenzym 4 (PDE4)
DK1478339T3 (da) Farmaceutiske formuleringer af antineoplastiske midler, specielt temozolomid, fremgangsmåder til fremstilling og anvendelse heraf
NO20005265D0 (no) Substituerte benzamider, deres fremstilling og anvendelse som inhibitorer av cystin-proteaser
NO20044388L (no) Derivater av N-[fenyl(piperidin-2yl)metyl]benzamid, fremgangsmate for fremstilling derav og anvendelse av de samme i terapeutika
IL158588A0 (en) Optical resolution of (1-benzyl-4-methylpiperidin-3-yl) - methylamine and the use thereof for the preparation of pyrrolo 2,3-pyrimidine derivatives as protein kinase inhibitors
AU6890800A (en) A novel crystalline form of disodium n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-D]- pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid salt and processes therefor
NO20034751D0 (no) Antranilsyreamider, deres fremstilling og anvendelse samt preparater
DK1373224T3 (da) Nye spirotricykliske derivater og deres anvendelse som phosphodiesterase 7 inhibitorer
DK1513516T3 (da) Substitueret 3-amino-thieno(2,3-b)-pyridin-2-carboxylsyreamid-forbindelser og fremgangsmåder til fremstilling og deres anvendelser
IL174942A0 (en) Derivatives of n-[phenyl(piperidine-2-yl)methyl] benzamide, preparation method thereof and applications of same in therapeutics
NO20040356L (no) Indaneddiksyrederivater og deres andvendelse som farmasoytiske midler, intermediater og fremgangsmate for fremstilling.
DK1326853T3 (da) Nye thiadiazoler og oxadiazoler og deres anvendelse som inhibitorer af phosphodiesterase 7
EE200300400A (et) Pürimidiiniühendid, nende valmistamismeetod ning kasutamine
EE200300435A (et) 4-(2-butüülamino)-2,7-dimetüül-8-(2-metüül-6-metoksüpürid-3-üül)[1,5-a]pürasolo-1, 3,5-triasiin, selle farmatseutiliselt vastuvõetavad eelravimid võifarmatseutiliselt vastuvõetavad soolad ning nendekasutamine
DK1353906T3 (da) Fremgangsmåde til fremstilling af (3-cyano-1H-indol-7-yl)(4-(4-fluorphenetyl)piperazin-1-yl)-methanon og salte deraf
EE05380B1 (et) FenletanoolamiiniÁkristallivorm,ÁselleÁvalmistamineÁjaÁsedaÁsisaldavadÁfarmatseutilisedÁkompositsioonid
NO20015042D0 (no) Fremgangsmåter for fremstilling av optisk aktive aminosyrederivater
AU2001290743A1 (en) Solid salt forms of n-(2-(4-(2-(1-methylethoxy)phenyl)-1-piperazinyl)ethyl)-2-oxo-1-piperidineacetamide
AU2003215677A1 (en) N-(morpholin-2yl) methyl acetamide derivatives as ccr-3 antagonists useful in the treatment of inflammatory diseases
DK1153015T3 (da) Pyrimidin-2,4,6-trioner som inhibitorer af matrix-metalloproteinaser
DK1392650T3 (da) Beskyttede tyrosinderivater, fremgangsmåde til deres fremstilling og deres anvendelse til fremstilling af O-(2-[18F]-fluorethyl)-L-tyrosin